Equine Rabies Immunoglobulin

PreclinicalBiologic

MMahidol University

Equine Rabies Immunoglobulin is one of 7 biologic programs targeting Obese Patients. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obese PatientsCompleted

Obese PatientsPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Obese Patients

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

Zovirax

BBp Consulting, Inc

Phase 1

1 3

Esmeron

FFresenius Kabi USA, LLC

Preclinical

2 4

Blood Puncture Site

AAssistance Publique Hopitaux De Marseille

Preclinical

1 5

IV Vancomycin

MMelinta Therapeutics, Inc.

Preclinical

1 6

Anesthetics

MMedical University of Vienna

Preclinical

1 7

Equine Rabies Immunoglobulin

MMahidol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Obese Patients1 trial

Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients

Completed·MMahidol University·N/A·NCT03093545·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Equine Rabies Immunoglobulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Equine Rabies Immunoglobulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Equine Rabies Immunoglobulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mahidol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMahidol University

Equine Rabies Immunoglobulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Obese Patients1 trial

References

Drug Info

Quick Facts

Related News